Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AMWC Asia-TDAC
Not Confirmed
Contact SupplierAMWC Asia-TDAC
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content
NEWS #PharmaBuzz
24 Mar 2021
// REUTERS
https://www.reuters.com/article/us-health-coronavirus-brazil-sputnik/brazil-could-approve-russian-coronavirus-vaccine-in-days-says-pharmaceutical-firm-idUSKBN2BF34V
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/medicamento+standor+tem+lote+suspenso+pela+anvisa
Drugs in Development
Details:
Documents supporting drugmaker Uniao Quimica’s application for emergency use of Sputnik V have been returned to the company because they did not meet its minimum criteria.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sputnik V
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 17, 2021
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data
Details : Documents supporting drugmaker Uniao Quimica’s application for emergency use of Sputnik V have been returned to the company because they did not meet its minimum criteria.
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
January 17, 2021
Details:
Sodium Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Heparin Sodium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Buranello e Rodrigues Consultoria
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2017
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Study With Heparin Sodium in Intravenous Administration
Details : Sodium Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2017
Details:
Amblyomin-X is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): Amblyomin-X
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Buranello e Rodrigues Consultoria
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 19, 2017
Study of Amblyomin-X in Advanced Solid Tumor
Details : Amblyomin-X is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 19, 2017
Details:
Sodium Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Heparin Sodium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Buranello e Rodrigues Consultoria
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2017
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Study With Heparin Sodium in Subcutaneous Administration
Details : Sodium Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 13, 2017
Details:
Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Menstruation Disturbances.
Lead Product(s): Levonorgestrel,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Hormone
Recipient: Azidus
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2011
Lead Product(s) : Levonorgestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Recipient : Azidus
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.
Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Menstruation Disturbances.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 29, 2011
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Brazil
Clobutinol HCl; Doxylamine Succinate
Uniao Quimica Farmaceutica Nacional
Dosage Form : Oral Solution; Oral Solu...
Brand Name : Hytós Plus
Dosage Strength : 48MG/15ML; 9MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Brazil
Regulatory Info :
Registration Country : Brazil
clobutinol hydrochloride; Doxylamine Succinate
Uniao Quimica Farmaceutica Nacional
Dosage Form : Syrup; Syrup
Brand Name : Hytós Plus
Dosage Strength : 4MG/100ML; 0.75MG/100M...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Brazil
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : Brazil
Clobutinol HCl; Doxylamine Succinate
Uniao Quimica Farmaceutica Nacional
Dosage Form : Oral Solution; Oral Solution
Brand Name : Hytós Plus
Dosage Strength : 48MG/15ML; 9MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Brazil
Regulatory Info :
Registration Country : Brazil
clobutinol hydrochloride; Doxylamine Succinate
Uniao Quimica Farmaceutica Nacional
Dosage Form : Syrup; Syrup
Brand Name : Hytós Plus
Dosage Strength : 4MG/100ML; 0.75MG/100M...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Brazil
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
